Nautilus Neurosciences (Bridgewater, NJ) near commercial-stage specialty neurology pharma focused on migraine and acute pain, closed a $14.5M Series A financing. Participants include Tailwind Capital.
_________________________________________________________________________
NOTE: New OnBioVC Friday feature coming, well…this Friday!

ImpactRx (Mt. Laurel, NJ) a commercial-stage provider of online content measuring the impact of pharmaceutical promotion on the prescribing behavior of the nation’s highest value physicians, closed a $1.2M Series E financing. Participants have included Mediphase Venture Partners, 3i Group, Oxford Bioscience Partners and Merck.

CicuLite (Saddle Brook, NJ) a clinical-stage medical device company focused on minimally invasive implantable devices for chronic heart failure, closed a $32.5M Series C financing. Participants include Forbion Capital Partners, Crédit Agricole Private Equity, Foundation Medical Partners and Oxford Bioscience Partners.

PTC Therapeutics (South Plainfield, NJ) a clinical-stage small molecule company focused on CF, hemophilia and muscular dystrophy, closed a $50M Series E financing. Participants include The Column Group, Delphi Ventures, CSFB Private Equity, HBM BioVentures and Novo Ventures.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Ophthotech (Princeton, NJ) a clinical-stage biopharmaceutical company focused on ophthalmic therapies for wet and dry age-related macular degeneration, closed a $30M Series B financing. Participants include Clarus Ventures, SV Life Sciences, Novo Ventures and HBM BioVentures.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Regado Biosciences (Basking Ridge, NJ) a clinical-stage biopharmaceutical company with an aptamer platform drug-antidote pairing system focused upon the anticoagulant market, closed a $40M Series D financing. Participants include Edmond de Rothschild Investment Partners, Domain Associates, Quaker Bioventures, Aurora Funds and Caxton Advantage Life Sciences Fund.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Lux Biosciences (Jersey City, NJ) a clinical-stage biotechnology company focused on ophthalmic diseases, closed a $50M Series B financing. Participants include HBM Bioventures, De Novo Ventures, Prospect Venture Partners, SV Life Sciences and International Biotechnology Trust.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

Tarsa Therapeutics (Boonton, NJ) a clinical stage small molecule company focused on osteoporosis closed a $24M Series A financing. Participants include MVM Life Science Partners, Quaker BioVentures and Novo Ventures.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

DNP Green Technology (Princeton, NJ) a development-stage bioagriculture company focused on processes for making bio-derived succinic acid and its derivatives for the production of chemicals and polymers, closed a $12M Series A financing. Participants include Sofinnova Partners, Mitsu Ventures, Samsung Ventures Investment Corporation, Cliffton Group, AquaRIMCO, Touradji Capital Management, Toyota Tsusho Corporation and Japan Asia [...]

VaxInnate (Cranbury, NJ) a clinical-stage vaccine company focused on infectious disease including flu, malaria, dengue, papillomavirus, and respiratory syncytial virus, closed a $30M Series D financing. Participants include Wellcome Trust, New Leaf Venture Partners, Canaan Partners, HealthCare Ventures, Oxford Bioscience Partners, MedImmune Ventures and CHL Medical Partners.